Showing results (161-170 of 291) with videos related to
Sort By:
Pageof 30
Internal Medicine (Tokyo, Japan)|September 20, 2019
Predictors of Insulin Secretion in Japanese Patients with Histopathologically-confirmed Non-alcoholic Fatty Liver DiseaseNorio Akuta, Yusuke Kawamura, Shunichiro Fujiyama, et al.Intervirology|April 7, 2005
Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis CYasuji Arase, Kenji Ikeda, Akihito Tsubota, et al.Intervirology|November 27, 2004
Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infectionYasuji Arase, Kenji Ikeda, Akihito Tsubota, et al.Intervirology|January 24, 2006
Efficacy of interferon therapy in elderly patients with chronic hepatitis CRikako Koyama, Yasuji Arase, Kenji Ikeda, et al.Journal of Gastroenterology|June 21, 2013
Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-upMariko Kobayashi, Tetsuya Hosaka, Fumitaka Suzuki, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 1, 2019
Advantage of liver stiffness measurement before and after direct-acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis CNobuhiko Ogasawara, Satoshi Saitoh, Norio Akuta, et al.Liver International : Official Journal of the International Association for the Study of the Liver|February 9, 2017
The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settingsHitomi Sezaki, Fumitaka Suzuki, Tetsuya Hosaka, et al.Journal of Gastroenterology|March 24, 2019
Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infectionsHitomi Sezaki, Fumitaka Suzuki, Tetsuya Hosaka, et al.Intervirology|March 27, 2004
Sustained negativity for HCV-RNA over 24 or more months by long-term interferon therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral loadYasuji Arase, Fumitaka Suzuki, Akihito Tsubota, et al.Journal of Medical Virology|August 10, 2018
Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antivirals regimensNorio Akuta, Hitomi Sezaki, Fumitaka Suzuki, et al.Pageof 30